Reshoring Pharma Manufacturing: The Operational Reality

If you've been following the news, you'd think the U.S. pharmaceutical manufacturing renaissance is already underway. The BIOSECURE Act is law. Tariff pressures are mounting. Most Favored Nation pricing deals are pushing companies toward domestic investment commitments. The political narrative is clear: bring manufacturing back to American soil.

And to be fair, the intent behind it isn't wrong. Reducing dependency on foreign suppliers for critical medicines is a legitimate national security and public health priority. The vulnerabilities in the global pharmaceutical supply chain are real, and anyone who works inside these supply chains knows it.

But there's a significant gap between the policy conversation and the operational reality. And from where I sit, working inside biotech supply chains every day, that gap is worth talking about honestly.

The Timeline Nobody Wants to Hear

Reshoring pharmaceutical manufacturing is not a matter of flipping a switch. It's not even a matter of building a facility and turning it on. The actual process of moving manufacturing operations from an established overseas partner to a new domestic site involves years of work, and that's if everything goes well.

Start with the tech transfer itself. Moving a manufacturing process from one site to another requires extensive process characterization, equipment qualification, and analytical method validation. For biologics, this is especially complex. You're not just replicating a recipe. You're replicating a living system in a new environment, and even small differences in equipment, raw materials, or operating conditions can affect the product.

Then there's the regulatory path. Any change to an approved manufacturing site requires FDA review and approval. Depending on the significance of the change, that could mean a Prior Approval Supplement, which comes with its own review timeline and potential inspection requirements. For products in clinical development, the regulatory burden is different but no less real. You're amending your IND, potentially running comparability studies, and managing the risk that any manufacturing change introduces uncertainty into your clinical program.

From start to finish, a full tech transfer to a new domestic manufacturing site can take three to five years for a straightforward process. For complex biologics, cell and gene therapies, or products with specialized manufacturing requirements, it can take longer. That's not a political timeline. That's an operational one.

The Investment Is Enormous

Building or expanding domestic manufacturing capacity requires capital on a scale that most biotech companies aren't positioned to deploy. We're talking about hundreds of millions of dollars for a single facility, before you account for the cost of the tech transfer itself, the regulatory work, the staffing, and the ongoing operational overhead.

For large pharmaceutical companies with commercial portfolios and steady revenue, the investment is significant but manageable. For small and mid-size biotechs, many of which are pre-revenue and reliant on venture funding, the math is much harder. These companies chose overseas CDMOs in the first place because the economics made sense. The cost advantage of manufacturing in certain regions isn't trivial, and domestic alternatives don't always exist at the scale or specialization they need.

The CHIPS Act provided a model for how government incentives can drive reshoring in critical industries. But so far, there's no equivalent for pharmaceutical manufacturing. Without meaningful financial incentives to offset the cost of domestic investment, many companies will face a difficult choice between compliance and financial viability.

The Workforce Isn't Ready

Even if the facilities get built and the capital gets deployed, there's a workforce problem that rarely makes it into the headlines. Pharmaceutical manufacturing requires highly specialized talent: process engineers, quality professionals, validation specialists, regulatory affairs experts, and skilled operators. The U.S. doesn't currently have enough of these people to support a meaningful expansion of domestic manufacturing capacity.

This isn't a training problem that gets solved in a semester. Building a qualified pharmaceutical manufacturing workforce takes years of education, hands-on experience, and regulatory knowledge that can't be shortcut. Companies that build new domestic facilities will be competing for the same limited talent pool, and that competition will drive up costs even further.

The Political Cycle Problem

Here's the part that concerns me most as someone who watches companies make long-term supply chain investments.

Pharmaceutical manufacturing decisions are measured in decades. A facility that breaks ground today won't be fully operational and validated for years. The return on that investment plays out over 10, 15, 20 years. But the policy environment that's driving these decisions changes every four years, sometimes more dramatically than anyone anticipates.

Companies that commit hundreds of millions of dollars to domestic manufacturing based on the current political and regulatory landscape are making a bet that the landscape will remain stable long enough for that investment to pay off. History suggests that's a risky assumption. Trade policies shift. Regulatory priorities change. Incentive programs get funded, defunded, and restructured. What's a national priority today may be a footnote in the next administration's agenda.

My honest assessment is that many companies will make public commitments to domestic manufacturing investment because the current environment demands it. Some will follow through. But a significant number will find that the timeline, the cost, and the shifting political winds make it impractical to fully execute on those commitments. The supply chain will adapt, as it always does, but the adaptation will be slower, messier, and more expensive than the headlines suggest.

What This Means for Biotech Companies Right Now

If you're running supply chain for a biotech company today, the reshoring conversation is something you need to be paying attention to, even if your current manufacturing partners aren't directly affected by the BIOSECURE Act or current tariff pressures.

The landscape is shifting, and the companies that navigate it well will be the ones that think clearly about their options without overreacting to the political moment. That means understanding your current supply chain exposure and where your vulnerabilities actually are. It means evaluating domestic alternatives honestly, including the cost, the timeline, and whether the capability actually exists at the scale you need. It means building flexibility into your supply chain strategy so you can adapt as the regulatory and political environment evolves, rather than making irreversible bets on a single scenario.

And it means being realistic about timelines. If your plan assumes you can transition manufacturing to a domestic site in 18 months, your plan is wrong. Build the actual timeline, with all the regulatory and operational complexity included, and plan accordingly.

The Honest Conversation

Reshoring pharmaceutical manufacturing is a worthy goal. The vulnerabilities in the current system are real, and reducing them matters. But worthy goals and operational reality don't always align on the same timeline, and pretending otherwise doesn't serve anyone.

The companies that will come out of this transition in the strongest position are the ones having honest conversations right now about what's feasible, what's realistic, and what the actual cost of these decisions will be. Not the political cost. The operational one.

Verant Consulting Group helps biotech companies evaluate and strengthen their manufacturing and supply chain strategies in a shifting regulatory landscape. If you're working through reshoring questions or supply chain risk planning, let's talk.